Small-cell lung cancerJACKMAN, David M; JOHNSON, Bruce E.Lancet (British edition). 2005, Vol 366, Num 9494, pp 1385-1396, issn 0140-6736, 12 p.Article

Noninvasive Detection of Response and Resistance in EGFR-Mutant Lung Cancer Using Quantitative Next-Generation Genotyping of Cell-Free Plasma DNAOXNARD, Geoffrey R; PAWELETZ, Cloud P; JÄNNE, Pasi A et al.Clinical cancer research (Print). 2014, Vol 20, Num 6, pp 1698-1705, issn 1078-0432, 8 p.Article

Radiographic assessment and therapeutic decisions at RECIST progression in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitorsNISHINO, Mizuki; CARDARELLA, Stephanie; DAHLBERG, Suzanne E et al.Lung cancer. 2013, Vol 79, Num 3, pp 283-288, issn 0169-5002, 6 p.Article

The Impact of Initial Gefitinib or Erlotinib versus Chemotherapy on Central Nervous System Progression in Advanced Non-Small Cell Lung Cancer with EGFR MutationsHEON, Stephanie; YEAP, Beow Y; LINDEMAN, Neal I et al.Clinical cancer research (Print). 2012, Vol 18, Num 16, pp 4406-4414, issn 1078-0432, 9 p.Article

Phase ii clinical trial of chemotherapy-naive patients ≥ 70 years of age treated with erlotinib for advanced non-small-cell lung cancerJACKMAN, David M; YEAP, Beow Y; FREIDLIN, Boris et al.Journal of clinical oncology. 2007, Vol 25, Num 7, pp 760-766, issn 0732-183X, 7 p.Article

Family history of lung cancer in never smokers with non-small-cell lung cancer and its association with tumors harboring EGFR mutationsGAUGHAN, Elizabeth M; CRYER, Sarah K; YEAP, Beow Y et al.Lung cancer. 2013, Vol 79, Num 3, pp 193-197, issn 0169-5002, 5 p.Article

Impact of Epidermal Growth Factor Receptor and KRAS Mutations on Clinical Outcomes in Previously Untreated Non-Small Cell Lung Cancer Patients: Results of an Online Tumor Registry of Clinical TrialsJACKMAN, David M; MILLER, Vincent A; CIOFFREDI, Leigh-Anne et al.Clinical cancer research (Print). 2009, Vol 15, Num 16, pp 5267-5273, issn 1078-0432, 7 p.Article

Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinibJACKMAN, David M; HOLMES, Alison J; LINDEMAN, Neal et al.Journal of clinical oncology. 2006, Vol 24, Num 27, pp 4517-4520, issn 0732-183X, 4 p.Article

Erlotinib Plus Bevacizumab in Previously Treated Patients With Malignant Pleural MesotheliomaJACKMAN, David M; KINDLER, Hedy L; YEAP, Beow Y et al.Cancer. 2008, Vol 113, Num 4, pp 808-814, issn 0008-543X, 7 p.Article

Effects of Erlotinib in EGFR Mutated Non-Small Cell Lung Cancers with Resistance to GefitinibCOSTA, Daniel B; NGUYEN, Kim-Son H; HUBERMAN, Mark S et al.Clinical cancer research (Print). 2008, Vol 14, Num 21, pp 7060-7067, issn 1078-0432, 8 p.Article

Response to low-dose ketoconazole and subsequent dose escalation to high-dose ketoconazole in patients with androgen-lndependent prostate cancerNAKABAYASHI, Mari; WANLING XIE; REGAN, Meredith M et al.Cancer. 2006, Vol 107, Num 5, pp 975-981, issn 0008-543X, 7 p.Article

Aggressive therapy for patients with non-small cell lung carcinoma and synchronous brain-only oligometastatic disease is associated with long-term survivalGRAY, Phillip J; MAK, Raymond H; KOZONO, David E et al.Lung cancer. 2014, Vol 85, Num 2, pp 239-244, issn 0169-5002, 6 p.Article

Volumetric Tumor Growth in Advanced Non-Small Cell Lung Cancer Patients With EGFR Mutations During EGFR-Tyrosine Kinase Inhibitor Therapy: Developing Criteria to Continue Therapy Beyond RECIST ProgressionNISHINO, Mizuki; DAHLBERG, Suzanne E; CARDARELLA, Stephanie et al.Cancer. 2013, Vol 119, Num 21, pp 3761-3768, issn 0008-543X, 8 p.Article

EGFR Mutation Is a Better Predictor of Response to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Carcinoma Than FISH, CISH, and ImmunohistochemistrySHOLL, Lynette M; YUN XIAO; JOSHI, Victoria et al.American journal of clinical pathology. 2010, Vol 133, Num 6, pp 922-934, issn 0002-9173, 13 p.Article

Development of Central Nervous System Metastases in Patients with Advanced Non-Small Cell Lung Cancer and Somatic EGFR Mutations Treated with Gefitinib or ErlotinibHEON, Stephanie; YEAP, Beow Y; BRITT, Gregory J et al.Clinical cancer research (Print). 2010, Vol 16, Num 23, pp 5873-5882, issn 1078-0432, 10 p.Article

Autocrine Production of Amphiregulin Predicts Sensitivity to Both Gefitinib and Cetuximab in EGFR Wildtype CancersYONESAKA, Kimio; ZEJNULLAHU, Kreshnik; LINDEMAN, Neal et al.Clinical cancer research (Print). 2008, Vol 14, Num 21, pp 6963-6973, issn 1078-0432, 11 p.Article